COMMUNIQUÉS West-GlobeNewswire

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
16/11/2024
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
16/11/2024
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic response to Lutetium-PSMA Beyond Lutetium-PSMA, these results are relevant to the [...]
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
16/11/2024
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received formal notice from [...]
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
15/11/2024
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
15/11/2024
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has notified The Nasdaq Stock Market, LLC (“Nasdaq”) of [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
15/11/2024
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
15/11/2024
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
15/11/2024
– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: [...]
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
15/11/2024
Data will be presented on Monday, November 18 th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego. LEGEND achieved its primary efficacy [...]
Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2
15/11/2024
Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego. L'étude LEGEND a atteint son critère principal d'efficacité en [...]
GROUPE SAFE - Mise à disposition du Rapport Financier Annuel 2023
15/11/2024
Mise à disposition du Rapport Financier Annuel 2023 Fleurieux-sur-l’Arbresle - France - le 15 novembre 2024 à 20h . Safe SA (la « Société ») annonce avoir déposé auprès de l’Autorité des Marchés Financiers et mis à la [...]
Award-winning Mind Food Body Ltd vows to end Destructive Workplace Eating Habits
15/11/2024
KENT, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Mind Food Body Ltd. , led by Hanna Longstaff, The Eating Behaviour Expert, has launched a new range of corporate wellness solutions designed to address one of the [...]
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
15/11/2024
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to [...]
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
15/11/2024
Eight participants achieved HBsAg loss at any time. Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United Kingdom, Nov. 15, [...]
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
15/11/2024
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving [...]
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
15/11/2024
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving [...]
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD)
15/11/2024
Phase 2 study results to be presented at The Liver Meeting ® 2024 of AASLD BJT-778 900 mg dosed every four weeks showed promising efficacy by Week 24: 100% virologic response with 50% of participants with undetectable [...]
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
15/11/2024
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. [...]
Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit
15/11/2024
Ipsen met en avant 3 nouvelles présentations ainsi que 8 abstracts dans le cadre de son portefeuille de maladies cholestatiques rares du foie au congrès 2024 de l’AASLD. L’utilisation d’Iqirvo a été approuvée aux États- [...]

Pages